These include lower expression of enhancer of zeste homolog 2 (EZH2) (23) and lower neutrophil-to-lymphocyte ratio (NLR) (24) in younger patients, reflecting lower invasion and metastasis of the tumor behavior in this age group. The gene discussed is EZH2; the disease is neoplasm.